BRIC–States Will not Save Big Pharma Single-Handedly

Pharmaceutical Industry BRIC–States Will not Save Big Pharma Single-Handedly

20.08.2013Editor: Dominik Stephan

The so–called BRIC–states Brazil, Russia, India and China are no magic bullet for the international pharmaceutical industry: A new study by Frost & Sullivan in fact indicates that we might have set our ambitions a little to high... According to the study, companies will have to estalish regional partnerships and engage in dialogue to be succesful in these markets.

Related Companies

Frost & Sullivan

AZO GmbH + Co. KG

TRM Filter d.o.o.

Frewitt fabrique de machines SA

Import taxes, protective laws and strong competion from locally produced generics press global pharma multis on the BRIC–markets, Frost & Sullivan analysts say. Despite the economic strong growth, these markets are no longer seen as the 'promised land' as which they were praised during the last decade.

But also the players in the pharmaceutical industry have not yet adapted to the local conditions, the study says: Neither are remedies designed for the specific desires and needs of these markets, nor are all sectors sufficiently developed. “For example the educational standrad of doctors outside the big Tier-1 cities is often not the same as in developed states. Missing partnerships with local administrations, NGOs and trade organisations are another important aspect and demonstrate the dommittment of companies to these states", explained Reenta Das of Frost & Sullivan.

The analysts expect that succes in these economies will not be achieved with cheap bulk products, but by adapting to the nature and development of the local markets. In fact, innovative technologies and business models might developed locally might also be adapted in Western staes as well.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:42267975)

Pharmaceutical Industry BRIC–States Will not Save Big Pharma Single-Handedly

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes